Kimya tangu 16 Okt UTCSiku ya 1

FDA approval and access to daraxonrasib

Taarifa mpya ya 1 kati ya 1Ya hivi karibuni29 Ago, 20:21 UTCSiku ya 1
FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer
Daraxonrasib targets the mutation behind more than 90% of cases and nearly doubled life expectancy in its pivotal trial, a landmark for a cancer with 13% five-year survival.
Tazama
Tulichojua kwanza
- FDA approved daraxonrasib on August 26, 2026.
- Approval was based on the pivotal randomized phase 3 RASolute 302 trial.
- Drug targets mutated RAS driving more than 90% of pancreatic cancers.
- Trial showed life expectancy nearly doubled, per USA Today.
Ambacho hakikuwa wazi wakati huo
- No verified price, coverage terms, or out-of-pocket burden in these excerpts.
- No verified exact survival months, side-effect rates, or full label details in these excerpts.
Tulichosema tungefuatilia
- Full RASolute 302 publication with survival, safety, and subgroup data.
- Label details, real-world tolerability, and access terms for previously treated patients.

Walioripoti

Walioripoti

9 vyombo vya habari · 11 vyanzo · 1 video

0 kati ya 9 vilikuwa vimeripoti kufikia wakati huu

News-Medicalnews-medical.net2
1. FDA approves first RAS-targeted therapy for metastatic pancreatic cancer
2. FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
Pancreatic Cancer Action Networkpancan.org2
1. FDA Approves RASONQUE™ (daraxonrasib)
2. First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know
ABC Newsabcnews.com1
1. FDA approves landmark pancreatic cancer drug that's shown to improve survival
CBS Newscbsnews.com1
1. FDA approves new pancreatic cancer drug that could extend patients' lives
Forbesforbes.com1
1. FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
HeyDay News1
1. New Pancreatic Cancer Pill Doubles Survival, But Cost Excludes Medicare Patientsvideo
Reutersreuters.com1
1. Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval
Scientific Americanscientificamerican.com1
1. U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease

Wanaohusika

Wanaohusika

Maeneo

Dana-Farber Cancer Institute
United States